Gilead Hepatitis C Drug Gets Accelerated Review Fox Business Chronic HCV is a major cause of liver cancer and liver transplantation in Europe and around the world, the company said. Chief Executive John C. Martin said that if approved, sofosbuvir has the potential to improve cure rates, while reducing the ... EMA Approves MAA for Gilead's (GILD) Sofosbuvir |
